Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19
have reported conflicting results. Objectives We sought to determine the safety and …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …

Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …

Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …

Background: COVID-19 patients are at high thrombotic risk. The safety and efficacy of
different anticoagulation regimens in COVID-19 patients remain unclear. Methods: We …

Importance Venous thromboembolism (VTE) is a common complication of COVID-19. It is
not well understood how hospitals have managed VTE prevention and the effect of …

Background Thrombosis may contribute to morbidity and mortality in Covid-19. We
hypothesized that therapeutic anticoagulation would improve outcomes in critically ill …

Introduction Although patients with severe COVID-19 are known to be at high risk of
developing thrombotic events, the effects of anticoagulation (AC) dose and duration on in …

Background Optimal thromboprophylaxis for hospitalized patients with coronavirus disease
2019 (Covid-19) is uncertain. Methods In an open-label, adaptive platform trial, we randomly …